Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baxdrostat in Primary Aldosteronism
NCT07800858Not yet recruiting
- Sponsor
- Queen Mary University of London
- Start
- Sep 2026
- Primary completion
- May 2028
- Countries
- 1
01
Overview
Open-label, single-arm trial of baxdrostat in primary aldosteronism (PA), sponsored by Queen Mary University of London. Primary endpoint: Change in total lesion uptake of [18F]-CETO in adrenal lesions at 8 months. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
baxdrostat
03
Conditions
primary aldosteronism (PA)
Beyond the preview
Go deeper on NCT07800858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07800858.